A comparison of the impact of screen-positive results obtained from ultrasound and biochemical screening for Down syndrome in the first trimester: A pilot study

Prenatal Diagnosis

Volumn 24, Issue 5, 2004, Pages 347-351

  Weinans, Martin J N ^a   Kooij, Loes ^b   Müller, Moira A ^c   Bilardo, Katia M ^c   Van Lith, Jan M M ^c   Tymstra, Tjeerd ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Biochemical screening; Down syndrome; First trimester; Nuchal translucency; Questionnaires

Indexed keywords

ADULT; ANXIETY; ARTICLE; CHEMICAL ANALYSIS; CHORION VILLUS SAMPLING; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COUNSELING; DOWN SYNDROME; FEMALE; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; NETHERLANDS; PILOT STUDY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; QUESTIONNAIRE; SCREENING TEST;

ADULT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; HUMANS; NECK; NETHERLANDS; PATIENT SATISFACTION; PILOT PROJECTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; QUESTIONNAIRES; ULTRASONOGRAPHY, PRENATAL;

EID: 2642541137     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.872     Document Type: Article

References (14)

1. Bilardo CM, Pajkrt E, de Graaf IM, Mol BW, Bleker OP. 1998. Outcome of fetuses with enlarged nuchal translucency and normal karyotype. Ultrasound Obstet Gynecol 11: 401-406.
2. Bilardo CM. 2001. Increased nuchal translucency and normal karyotype: coping with uncertainty. Ultrasound Obstet Gynecol 17: 99-101.
3. De Graaf IM, Tijmstra Tj, Bleker OP, van Lith JMM. 2002. Women's preference in Down syndrome screening. Prenat Diagn 22: 624-629.
4. Gekas J, Gondry J, Mazur S, Cesbron P, Thepot F. 1999. Informed consent to serum screening for Down syndrome: Are women given adequate information? Prenat Diagn 19: 1-7.
5. Green JM. 1994. Serum screening for Down's syndrome: experiences of obstetricians in England and Wales. BMJ 309: 769-772.
6. Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A. 1998. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 338: 955-961.
7. Hyett JA. 2002. Increased nuchal translucency in fetuses with a normal karyotype. Prenat Diagn 22: 864-868.
8. Kornman LH, Wortelboer MJM, Beekhuis JR, Morssink LP, Mantingh A. 1997. Women's opinions and the implications of first-versus second-trimester screening for fetal Down's syndrome. Prenat Diagn 17: 1011-1018.
9. Nicolaides KH, Heath V, Cicero S. 2002. Increased fetal nuchal translucency at 11-14 weeks. Prenat Diagn 22: 308-315.
10. Senat MV, De Keersmaecker B, Audibert F, Montcharmont G, Frydman R, Ville Y. 2002. Pregnancy outcome in fetuses with increased nuchal translucency and normal karyotype. Prenat Diagn 22: 345-349.
11. Snijders RJ, Noble P, Sebine N, Souka A, Nicolaides KH. 1998. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thikness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 352: 343-346.
12. Souka AP, Krampl E, Bakabalis S, Heath V, Nicolaides KH. 2001. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol 18: 9-17.
13. Weinans MJN, Huijssoon AMG, Tymstra Tj, Gerrits MCF, Beekhuis JR, Mantingh A. 2000. How women deal with the results of serum screening in the second trimester of pregnancy. Prenat Diagn 20: 705-708.
14. Williams C, Alderson P, Farsides B. 2002. Dilemmas encountered by health practitioners offering nuchal translucency screening: a qualitative case study. Prenat Diagn 22: 216-220.